Overview

P3 Long Term Safety Study of Once Daily SB204 in Acne

Status:
Completed
Trial end date:
2017-04-27
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.
Phase:
Phase 3
Details
Lead Sponsor:
Novan, Inc.
Collaborator:
Chiltern International Inc.